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Abstract
Chloromethyl polystyrene resin was reacted with 5-hydroxysalicylaldehyde in the presence of
potassium carbonate to afford polymer-bound 2-hydroxybenzaldehyde. Subsequent reduction with
borane solution produced polymer-bound 2-hydroxybenzyl alcohol. The reaction of immobilized 2-
hydroxybenzyl alcohol with appropriate phosphitylating reagents yielded solid-phase cycloSaligenyl
mono-, di-, and triphosphitylating reagents, which were reacted with unprotected nucleosides,
followed by iodine oxidation, deprotection of cyanoethoxy groups, and the basic cleavage,
respectively, to afford 5′-O-nucleoside mono-, di-, and triphosphoramidates in 52-73% overall yield.
Antiviral and antitumor nucleoside analogs undergo three phosphorylation steps by cellular
kinases to generate nucleoside 5′-triphosphates that act as competitive inhibitors of DNA
polymerases or incorporate into DNA and cause chain termination.1 The first phosphorylation
step is often the rate-limiting step. Thus several nucleoside phosphoramidate derivatives have
*E-mail: kparang@uri.edu.
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been synthesized as prodrugs with the aim of delivering the corresponding 5′-mononucleotide
intracellularly and bypassing the initial phosphorylation step.2-6 A number of
phosphoramidate derivatives of antiviral and antitumor nucleosides have demonstrated to have
enhanced activity and reduced cytotoxicity when compared with their corresponding parent
nucleosides.3,6-8 Furthermore, oligonucleotide phosphoramidates have attracted considerable
attention as potential antisense agents because of their stability toward nucleases and being
able to form a duplex with complementary DNA or RNA sequences with higher affinity.9,
10 Catalysis of many hydrolases and nucleases also occur through nucleoside phosphoramidate
intermediates.11,12 Therefore, the synthesis of nucleoside phosphoramidates and
phosphoramidate-based pronucleotides and oligonucleotides are subjects of considerable
interest in nucleic acid research. The facile synthesis of larger quantities of phosphoramidate
derivatives is essential for studying their biological properties.
The reported solution-phase methods for the synthesis of nucleoside 5′-phosphoramidates
include the reaction of nucleoside diphosphates, triphosphates, chlorophosphates, H-
phosphonates, or trimethaphosphates, with amines13-16 in the presence of a base and/or a
coupling reagent (e.g., N-carbodiimide derivatives13,17,18 or trimethylsilyl chloride15,19).
Alternatively, highly reactive phosphoramidate precursors (e.g., phosphoryldichloride
derivatives or bis(benzotriazolyl)phosphoramidates) have been used in reaction with
nucleosides for the synthesis nucleoside phosphoramidates.6 These methods have one or more
disadvantages, such as the requirement for the synthesis of precursor nucleoside phosphates
or phosphoramidates, the poor solubility of precursors in organic solvents, tedious purification
of final products from intermediates and starting reagents, and low or moderate overall yields.
We have previously reported the solid-phase synthesis of nucleoside mono-, di-, and
triphosphates with high regioselectivity using polymer-bound linkers of p-hydroxybenzyl
alcohol or p-acetoxybenzyl alcohol.20-4
CycloSaligenyl (cycloSal)-phosphate triesters of several nucleoside analogs have been
designed as a pH-driven nucleotide delivery system.25-28 As part of our ongoing efforts to
synthesize organophosphorus compounds,29 we report the synthesis of immobilized cycloSal
phosphitylating reagents and their application for the synthesis of nucleoside mono-, di-, and
triphosphoramidates to circumvent one or more of the problems associated with the solution-
phase methods. To the best of our knowledge, this is the first paper on the synthesis of polymer-
bound cycloSal phosphitylating reagents. Mono-, di-, and triphosphitylating reagents were first
immobilized on polystyrene resin-bound linker of 2-hydroxybenzyl alcohol. Coupling reaction
of unprotected nucleosides with the immobilized reagent followed by iodine oxidation,
deprotection, and basic cleavage afforded nucleoside mono-, di-, and triphosphoramidates.
The advantages of this solid-phase strategy included: (i) The immobilization of hindered
phosphitylating reagents on a rigid polymer-bound linker allowed for the regioselective
reaction with the most reactive hydroxyl group in the presence of an excess of unprotected
nucleosides to afford monosubstituted final products; (ii) Unprotected nucleosides were used
instead of precursor nucleoside phosphate derivatives; (iii) Excess of nucleosides and unreacted
reagents were removed in each step by washing the resins. Furthermore, the modified linker
remained trapped on the resins. This facilitated isolation and purification of monosubstituted
final products; and (iv) This strategy allowed the synthesis of nucleoside 5′-O-mono-, di-, and
triphosphoramidates from the same polymer-bound linker.
Scheme 1 illustrates the synthesis of diphosphitylating and triphosphitylating reagents (4 and
7). Phosphorus trichloride was subjected to reaction with 3-hydroxypropionitrile (1 equiv) in
the presence of 2,6-lutidine in anhydrous THF to yield 2-cyanoethyl phosphorodichloridate
(1). The subsequent reaction of 1 with diisopropylamine (1 equiv) in the presence of 2,6-
lutidine afforded 2-cyanoethyl diisopropylchlorophosphoramidite 2. Addition of water (1
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equiv) and 2,6-lutidine gave the intermediate 3 that was reacted with phosphorus trichloride
(1 equiv) in the presence of 2,6-lutidine to afford the diphosphitylating reagent (4, 93%)
In a separate reaction, 2-cyanoethyl phosphorodichloridate (1) was reacted with the
intermediate 3 (1 equiv) in the presence of 2,6-lutidine in anhydrous THF to yield 5. Compound
5 was immediately treated with water (1 equiv) and phosphorus trichloride (1 equiv),
respectively, in the presence of 2,6-lutidine to yield the triphosphitylating reagent (7, 87%).
The diphosphitylating and triphosphitylating reagents (4 and 7) were used immediately in
coupling reactions with the polymer-bound 2-hydroxybenzyl alcohol. Compounds 4 and 7 were
reacted with water and the chemical structures of their dihydroxy forms were confirmed by
high-resolution time-of-flight electrospray mass spectrometry.
Scheme 2 shows the synthesis of nucleoside mono-, di, and triphosphoroamidates from
polymer-bound 2-hydroxybenzylalcohol (10). Chloromethyl polystyrene resin (8) was reacted
with 5-hydroxysalicylaldehyde in the presence of sodium iodide and potassium carbonate to
afford polymer-bound 2-hydroxybenzaldehyde (9). Reduction of the aldehyde group in 9 in
the presence of borane solution (1M) produced polymer-bound 2-hydroxybenzyl alcohol
(10), which was reacted with phosphorus trichloride or N,N-diisopropyl phosphoramidous
dichloride in the presence of 2,6-lutidine to produce the corresponding polymer-bound
cycloSal monophosphitylating reagents, 11 and 12, respectively.
Similarly, the reaction of 10 with diphosphitylating and triphosphitylating reagents, 4 and 7,
in the presence of 2,6-lutidine produced polymer-bound cycloSal diphosphitylating and
triphosphitylating reagents (13 and 14), respectively. The treatment of 11 or 12 with excess of
unprotected nucleosides (e.g., 3′-azido-3′-deoxythymidine (a), adenosine (b), 3′-fluoro-3′-
deoxythymidine (c), 2′,3′-didehydro-2′,3′-dideoxythymidine (d), thymidine (e), 2′-
deoxyadenosine (f), 2′-deoxycytidine (g), and 3′-deoxyguanidine (h)) in the presence of
pyridine or 5-(ethylthio)-1H-tetrazole, respectively, gave 15a–h. Similarly, reaction of 13 and
14 with excess of 3′-azido-3′-deoxythymidine (a) and adenosine (b) in the presence of 5-
(ethylthio)-1H-tetrazole afforded 16–17a,b. The most reactive hydroxyl group of unprotected
nucleosides reacted selectively with hindered polymer-bound reagents (11–14) when an excess
of nucleoside was used in coupling reaction.
Iodine oxidation of 15a–h and 16–17a,b yielded the corresponding polymer-bound nucleosides
5′-O-monophosphate (18a–h), diphosphate (19a,b), and triphosphate triester derivatives
(20a,b). The removal of the cyanoethoxy group with DBU in 19–20a,b afforded the
corresponding polymer-bound nucleosides 21–22a,b.
The cleavage of polymer-bound compounds 18a–h and 21–22a,b was carried out under basic
conditions (NH4OH). The intramolecular cleavage mechanism of final products from (23a–
h and 24–25a,b) is shown in Scheme 2. The cleavage relies on a nucleophilic attack on the
phosphate triester by ammonia and a subsequent hydrolysis pathway to yield the nucleoside
phosphoramidate derivatives. The reaction of ammonium hydroxide on resin 26 at the same
time produced the linker-trapped resin (27), which was separated from the final products by
filtration. The crude products had a purity of 68-92% and were purified on the C18 Sep-Pak
cartridges to afford 5′-O-nucleoside monophosphoramidates, diphosphoramidates, and
triphosphoramidates (28a–h, 29–30a,b, Scheme 2) in 52-73% overall yield (calculated from
11–14, Table S1, see Supporting Information). The products were characterized by 1H
NMR, 13C NMR, 31P NMR, and high-resolution mass spectrometry (ESI-TOF).
This is the first report of the synthesis of solid-phase cycloSal phosphitylating reagents and
their application for the preparation of nucleoside 5′-O-mono- di-, and triphosphoramidates.
The solid-phase strategy allowed facile synthesis and purification of nucleoside 5′-
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phosphoramidate derivatives from unprotected nucleosides by removing the unreacted
reagents by washing in each step.
As a typical procedure (Scheme 2), 3′-azido-3′-deoxythymidine (a, 1 mmol, 4 equiv) and 5-
(ethylthio)-1H-tetrazole (4 equiv) were dissolved in dry DMSO (3 mL) and were added to
swollen 13 (229 mg, 0.25 mmol, 1.09 mmol/g) in THF (5 mL). The mixture was shaken for
28 h at room temperature. The resin was collected by filtration and washed with DMSO (2 ×
10 mL) and THF (2 × 10 mL), respectively, and dried under vacuum to give 16a (267 mg).
Iodine solution in pyridine/water (98:2 v/v) (1.5 equiv, 1.5 mL, 0.5 M) was added to swollen
resin 16a in THF (5 mL). After 15 min shaking at room temperature, the resin was collected
by filtration and washed with pyridine (2 × 10 mL), THF (2 × 10 mL), and DCM (2 × 10 mL),
respectively, and was dried overnight at room temperature under vacuum to give 19a (273 mg).
DBU (2 mmol) was added to swollen resin 19a in THF (5 mL). After 48 h shaking of the
mixture at room temperature, the resin was collected by filtration and washed with THF (3 ×
15 mL) and DCM (3 × 15 mL), respectively, and dried overnight at room temperature under
vacuum to give 21a (244 mg). NH4OH (30%, 3 mL) was added to swollen resin 21a in THF
(3 mL). After 75 min shaking of the mixture at room temperature, the resin was collected by
filtration and washed with MeOH (2 × 10 mL). The solvents of filtrate solution were
immediately evaporated at room temperature. The residue was mixed with Rexyn® 101 (H)
(hydrogen form, 500 mg, 5.72 meq/g) in water:dioxane (75:25 v/v, 3 mL) for 15 min. After
filtration, the solvents were removed using lyophilization and the crude products were purified
on C18 Sep-Pak using appropriate solvents. The solvents were evaporated and the residues
were dried under vacuum at −20 °C to yield 29a.
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Scheme 1.
Synthesis of Diphosphitylating and Triphosphitylating Reagents (4 and 7).
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Scheme 2.
Synthesis of Nucleoside Monophosphoramidates 28a–h, Diphosphoramidates, and
Triphosphoramidates 29-30a–b on the Solid Phase Using Polymer-Bound Linker 10.
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